MAPT and Alzheimer disease: As genetic models (e.g., 5xFAD, 3xTg‐AD, and EFAD) provide insight into amyloid and tau pathology, pharmacologic models offer a simpler but effective way to study the role of other factors (e.g., oxidative stress and neuroinflammation), whereas aging models, although somewhat less specific, further contribute to our understanding of AD and its progression.